Epiminder has ramped up enrolment in its DETECT study, contracting 18 US medical centres and maintaining a robust $83.8 million cash position to fund its Minder device commercialisation through 2028.
- DETECT study expands to 18 US centres
- 15 patients enrolled, targeting 210 by mid-2027
- G1 Minder device development on track
- Strong $83.8m cash supports operations into 2028
- Q3 net cash outflow $5.7m, below forecast
DETECT Study Gains Momentum Across US Medical Centres
Epiminder Limited (ASX:EPI) has significantly accelerated enrolment in its DETECT study, now contracted with 18 leading US medical centres including Stanford University, the University of South Florida, Wake Forest University, the University of North Carolina, and Indiana University. Patient enrolments have jumped from just 3 at the end of February 2026 to 15 as of March, positioning the company on track to meet its goal of 25 participants by the end of May and ultimately 210 patients by mid-2027. This expansion builds on the initial five-centre launch earlier this year and reflects growing clinical confidence in the Minder® implantable continuous EEG monitoring system, which remains the first FDA-authorised device of its kind for epilepsy monitoring. The company’s CEO, Rohan Hoare, highlighted the strong institutional interest as a key indicator of both clinical and commercial potential, reinforcing its planned full market rollout in early 2028.
G1 Minder Device Development and Regulatory Timeline
Development of the next-generation G1 Minder device remains on schedule for completion by the end of the first half of calendar 2027, with a planned FDA submission in the second half of that year. This timeline is critical to underpinning Epiminder’s commercialisation strategy, dovetailing with the ongoing DETECT study that supports the clinical value proposition following the 2026 Medicare reimbursement determination. The company’s progress on both fronts suggests a coordinated push toward broader US market penetration.
Financial Position Supports Extended Commercialisation Horizon
Epiminder reported a strong cash balance of $83.8 million as at 31 March 2026, down slightly from $89.5 million at the end of December 2025 following its $125 million IPO in late 2025. The company’s net operating cash outflow for Q3 FY26 was $5.7 million, significantly lower than the prior quarter’s $25.2 million outflow, largely due to slower invoicing by US medical centres during the DETECT study’s start-up phase. This timing effect is expected to reverse in FY27. Key expenditure categories, including research and development and staff costs, remained steady or slightly lower, reflecting operational efficiencies. Notably, Epiminder paid $2.16 million to its largest shareholder Cochlear Ltd for R&D services controlled by Epiminder management, alongside $90,000 in director fees for the quarter.
This financial discipline and cash runway are expected to fund Epiminder’s commercialisation plans well into 2028, supporting continued site contracting and patient enrolment through Q4 FY26. The company now forecasts a 2H FY26 cash burn of approximately $17 million, down from earlier guidance, reflecting the invoicing delays.
Strategic Implications of DETECT and Commercial Rollout
The DETECT study is pivotal for Epiminder, designed to demonstrate the superiority of continuous EEG monitoring with Minder over standard care in identifying clinically actionable events in drug-resistant epilepsy patients. The study’s success will not only validate the device’s clinical utility but also underpin reimbursement and market adoption strategies. Epiminder’s ability to secure and expand contracts with prestigious US medical centres, including recent additions like Stanford and Wake Forest, signals strong institutional buy-in. This momentum follows the company’s successful $125 million IPO and US rollout plans and builds on the initial five-centre DETECT study launch earlier this year.
However, the slower invoicing cycle during the study’s early phase introduces some cash flow timing uncertainty, which will require monitoring as enrolment scales. The company’s focus on maintaining a strong cash position while advancing clinical milestones will be crucial in navigating this phase.
Bottom Line?
Epiminder’s steady enrolment acceleration and solid cash reserves position it well for a 2028 market launch, though near-term cash flow timing warrants close attention.
Questions in the middle?
- Will patient enrolment accelerate to meet the 210-patient target by mid-2027?
- How will the FDA respond to the G1 Minder device submission in 2H 2027?
- Can invoicing delays during study start-up be fully resolved in FY27?